A new predictor for prediabetes: Chemerin

Year 2023, Volume: 15 Issue: 1, 52 - 58, 15.03.2023

Emine Ergün , Arzu Or Koca , Esin Beyan , Derun Taner Ertuğrul , Tolga Akkan , Kürşat Dal

https://doi.org/10.18521/ktd.1148541

Abstract

Objective: It was aimed to investigate irisin and chemerin levels in prediabetic individuals and their value in predicting prediabetes.
Method: Thirty-eight prediabetic patients aged 18-65 years (22 impaired fasting glucose (IFG), 10 impaired glucose tolerance (IGT), 6 patients with coexisting IFG and IGT) and thirty-five healthy volunteers were included in which was designed as a cross-sectional study. The basic demographic characteristics of all participants in the case and control groups were compared with the serum chemerin, irisin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), high-density lipoprotein (HDL-cholesterol), low-density lipoprotein (LDL-cholesterol), triglyceride (TG), free thyroxine (sT4), and thyroid-stimulating hormone (TSH) levels.
Result: Serum chemerin level was found to be higher in the prediabetic group (p=0.03), while no significant difference was found for the irisin level between the two groups. In the multivariate logistic regression analysis, we showed that chemerin was an independent risk factor in predicting prediabetes. There was a positive correlation (p=0.01, r=0.279) between all participants' body mass index (BMI) and chemerin level and a negative correlation between irisin level and high-density lipoprotein cholesterol (HDL-C) level, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (p=0.04 r=-0.295, p=0.01 r=-0.407, respectively).
Conclusion: Chemerin is a new generation chemokine that predicts prediabetes. Studies aimed at irisin and chemerin may provide important role to prevent the prediabetes to Type 2 diabetes progression.

Keywords

Chemerin, Diabetes mellitus, Irisin, Prediabetic state, Predictive value of tests

Prediyabet için yeni bir prediktör: Kimerin

Abstract

Amaç: Prediyabetik bireylerde irisin ve kimerin düzeylerini ve bunların prediyabeti öngörmedeki değerini araştırmak amaçlandı.
Metod: Kesitsel bir çalışma olan dizayn edilen çalışmamıza; 18-65 yaş arası 38 prediyabetik hasta (22 bozulmuş açlık glukozu (IFG), 10 bozulmuş. glukoz toleransı (IGT), 6 IFG ve IGT birlikte bulunan hasta) ve 35 gönüllü sağlıklı kişi dahil edildi. Vaka ve kontrol grubundaki tüm katılımcıların temel demografik özellikleri ile serum kimerin, irisin, kreatinin, Alanin Aminotransferaz (ALT), Aspartat Aminotransferaz (AST), düşük dansiteli lipoprotein (LDL-kolesterol), yüksek dansiteli lipoprotein (HDL-kolesterol), trigliserit (TG), serbest tiroksin (sT4) ve tiroid stimülan hormon (TSH) düzeylerinin sonuçları karşılaştırıldı.
Bulgular: Her iki grup arasında irisin düzeyi için fark saptanmazken, kimerin düzeyi prediyabetik grupta daha yüksek saptandı (p=0.03). Yaptığımız çok değişkenli lojistik regresyon analizinde kimerinin prediyabeti ön gördürücü bağımsız bir risk faktörü olduğunu gösterdik. Ayrıca tüm katılımcıların beden kitle indeksi (BKİ) ile kimerin düzeyi arasında pozitif korelasyon (p=0.01, r=0.279); irisin düzeyi ile high density lipoprotein kolesterol (HDL-C) düzeyi ve Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) arasında negatif korelasyon (sırasıyla; p=0.04 r=-0.295, p=0.01 r=-0.407) saptadık.
Sonuç: Kimerin prediyabeti predikte eden yeni nesil bir kemokindir. İrisin ve kimerin hedefli yeni çalışmalar prediyabetin diyabete dönüşmesinin önlenmesinde önemli aşamalar sağlayabilir.

Keywords

Kimerin, Diyabetes mellitus, İrisin, Prediyabetik durum, Testlerin prediktif değeri

References

• 1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al.; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 th edition. Diabetes Res Clin Pract. 2019;157:107843.
• 2. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379:2243-51.
• 3. Bobbert T, Schwarz F, Fischer-Rosinsky A, Maurer L, Möhlig M, Pfeiffer AFH et al. Chemerin and prediction of Diabetes mellitus type 2. Clin Endocrinol (Oxf). 2015;82:838-43.
• 4. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci. 2009;30:234-9.
• 5. Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides. 2014;56:94-110.
• 6. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-8.
• 7. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:217-21.
• 8. Takahashi M, Okimura Y, Iguchi G, Nishizawa H, Yamamoto M, Suda K et al. Chemerin regulates β-cell function in mice. Sci Rep. 2011;1:123.
• 9. Lee MK, Chu SH, Lee DC, An KY, Park J-H, Kim DI et al. The association between chemerin and homeostasis assessment of insulin resistance at baseline and after weight reduction via lifestyle modifications in young obese adults. Clin Chim Acta. 2013;421:109-15.
• 10. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:15-33.
• 11. Morris MR, Ludwar BCh, Swingle E, Mamo MN, Shubrook JH. A New Method to Assess Asymmetry in Fingerprints Could Be Used as an Early Indicator of Type 2 Diabetes Mellitus. J Diabetes Sci Technol. 2016;10:864-71.
• 12. Castro AV, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and comorbidities? Mechanisms of association. Arq Bras Endocrinol Metabol. 2014;58:600-9.
• 13. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010;72:342-8.
• 14. Chakaroun R, Raschpichler M, Klöting N, Oberbach A, Flehmig G, Kern M et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism. 2012;61:706-14.
• 15. Ebert T, Gebhardt C, Scholz M, Wohland T, Schleinitz D, Fasshauer M et al. Relationship Between 12 Adipocytokines and Distinct Components of the Metabolic Syndrome. J Clin Endocrinol Metab. 2018;103:1015-23.
• 16. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie A et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009;94:3085-8.
• 17. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-94.
• 18. Osman MM, El-mageed AIA, El-hadidi E, Shahin RSK, Mageed NAAA. Clinical utility of serum chemerin as a novel marker of metabolic syndrome and type 2 diabetes mellitus. Life Sci J 2012;9:1098-108.
• 19. Gateva A, Assyov Y, Tsakova A, Kamenov Z. Classical (adiponectin, leptin, resistin) and new (chemerin, vaspin, omentin) adipocytokines in patients with prediabetes. Horm Mol Biol Clin Investig. 2018;34.
• 20. Ernst MC, Issa M, Goralski KB, Sinal CJ. Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology. 2010;151:1998-2007.
• 21. Ernst MC, Haidl ID, Zúñiga LA, Dranse HJ, Rourke JL, Zabel BA et al. Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology. 2012;153:672-82.
• 22. Kralisch S, Weise S, Sommer G, Lipfert J , Lossner U, Bluher M et al. Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept. 2009;154:102-6.
• 23. Meder W, Wendland M, Busmann A, Kutzleb C, Spodsberg S, John H et al. Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett. 2003;555:495-9.
• 24. Liu JJ, Wong MD, Toy WC, Tan CSH, Liu S, Ng XW et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:365-9.
• 25. Wang L, Song J, Wang C, Lin P, Liang K, Sun Y et al. Circulating Levels of Betatrophin and Irisin Are Not Associated with Pancreatic β-Cell Function in Previously Diagnosed Type 2 Diabetes Mellitus Patients. J Diabetes Res. 2016;2016:2616539.
• 26. Yang M, Chen P, Jin H, Xie X, Gao T, Yang L et al. Circulating levels of irisin in middle-aged first-degree relatives of type 2 diabetes mellitus - correlation with pancreatic β-cell function. Diabetol Metab Syndr. 2014;6:133.
• 27. Liu S, Du F, Li X, Wang M, Duan R, Zhang J et al. Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic β cells. PLoS One. 2017;12:e0175498.
• 28. Moon HS, Dincer F, Mantzoros CS. Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism. 2013;62:1131-6.
• 29. Zhu D, Wang H, Zhang J, Zhang X, Xin C, Zhang F et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015;87:138-47.
• 30. Huh JH, Ahn SV, Choi JH, Koh SB, Chung CH. High Serum Irisin Level as an Independent Predictor of Diabetes Mellitus: A Longitudinal Population-Based Study. Medicine (Baltimore). 2016;95:e3742.